The overarching goal of the project is to discover and translate knowledge regarding the biology ofpulmonary premalignancy to reduce lung cancer burden through 1) the discovery and validation of clinicallyuseful biomarkers of risk and 2) the development of effective chemopreventive treatments. Biomarkers oflung cancer risk can have a variety of clinical uses, including population screening for early detection,defining high risk populations and as aids in guiding clinical decision making in settings of CT detectednodules of indeterminate etiology. Regardless of the outcome of ongoing randomized controlled trials oflung cancer screening using CT, there will be an increasing clinical need for risk biomarkers to guidedecisions on management of lung nodules detected by CT. New knowledge regarding the biology ofpulmonary premalignancy is being translated to novel chemoprevention strategies by this and other SPOREprojects.
Our Specific Aims are to:
Specific Aim 1. Identify and validate biomarkers of lung cancer in sputum, bronchial epithelium, BAL andblood. We will focus on biomarkers with considerable preliminary support, including atypia, gene promoterhypermethylation and chromosomal aneusomy in sputum, as well as on the development of newapproaches, including these same markers and protein expression in bronchial epithelium andbronchoalveolar lavage. We will take advantage of unique prospective cohorts of subjects with biologicalsamples harvested and stored and in whom both prevalent and incident lung cancer is tracked by a team ofepidemiology staff to carry out cross sectional and longitudinal nested case control studies.
Specific Aim 2. Validate the clinical utility of sputum biomarkers in the context of the NLST ACRIN Trial.The most promising sputum markers from Specific Aim 1 will be validated as a complementary set ofbiomarkers in groups of subjects strategically defined and sampled from a trial of CT screening. Analyseswill assess the performance of this biomarker panel for lung cancer screening as well as for its utility inassisting in clinical decisions regarding the management of pulmonary nodules of undeterminedsignificance.
Specific Aim 3. Conduct Phase II chemoprevention trials to prioritize agents for testing in Phase III trials.The current lloprost chemoprevention trial will be completed in early 2008. We will analyze the responseand develop a successor trial based on a PPAR gamma agonist as supported by preclinical data fromProject 3.Our proposal will have important implications for early detection, diagnosis and prevention of lung cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-14
Application #
7448825
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
14
Fiscal Year
2008
Total Cost
$183,464
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503

Showing the most recent 10 out of 435 publications